GB0102075D0 - Process - Google Patents

Process

Info

Publication number
GB0102075D0
GB0102075D0 GBGB0102075.9A GB0102075A GB0102075D0 GB 0102075 D0 GB0102075 D0 GB 0102075D0 GB 0102075 A GB0102075 A GB 0102075A GB 0102075 D0 GB0102075 D0 GB 0102075D0
Authority
GB
United Kingdom
Prior art keywords
liquid
particles
temperature
substance
modulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0102075.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB0102075.9A priority Critical patent/GB0102075D0/en
Publication of GB0102075D0 publication Critical patent/GB0102075D0/en
Priority to BR0206439-1A priority patent/BR0206439A/en
Priority to AU2002225193A priority patent/AU2002225193C1/en
Priority to MXPA03006537A priority patent/MXPA03006537A/en
Priority to PT02715546T priority patent/PT1357901E/en
Priority to US10/250,868 priority patent/US7108867B2/en
Priority to SI200230521T priority patent/SI1357901T1/en
Priority to IL15672002A priority patent/IL156720A0/en
Priority to CN02804101.1A priority patent/CN1298312C/en
Priority to EP02715546A priority patent/EP1357901B1/en
Priority to ES02715546T priority patent/ES2281509T3/en
Priority to DK02715546T priority patent/DK1357901T3/en
Priority to DE60218285T priority patent/DE60218285T2/en
Priority to AT02715546T priority patent/ATE354352T1/en
Priority to NZ526942A priority patent/NZ526942A/en
Priority to JP2002559008A priority patent/JP4175892B2/en
Priority to CA002433838A priority patent/CA2433838A1/en
Priority to PCT/GB2002/000261 priority patent/WO2002058674A2/en
Priority to KR1020037009726A priority patent/KR100853596B1/en
Priority to HK04105963.8A priority patent/HK1063157B/en
Priority to ZA200304953A priority patent/ZA200304953B/en
Priority to IL156720A priority patent/IL156720A/en
Priority to NO20033241A priority patent/NO20033241D0/en
Priority to US11/521,631 priority patent/US7829123B2/en
Priority to CY20071100570T priority patent/CY1106550T1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

A process for preparing particles of a substance, such as a protein or polypeptide, comprising: (a) preparing a first liquid comprising water, the substance and a modulator, wherein the modulator has a solubility in water which decreases with increasing temperature; and (b) contacting the first liquid with a second liquid comprising a fluid gas and an organic solvent using an anti-solvent fluid gas technique under conditions of temperature and pressure which result in the precipitation of particles comprising the substance, wherein the temperature of the first liquid is at or above the cloud point temperature of the first liquid when the first liquid contacts the second liquid. Also claimed are particles obtained according to the process and compositions containing the particles.
GBGB0102075.9A 2001-01-26 2001-01-26 Process Ceased GB0102075D0 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
GBGB0102075.9A GB0102075D0 (en) 2001-01-26 2001-01-26 Process
BR0206439-1A BR0206439A (en) 2001-01-26 2002-01-21 Process for the preparation of particles of a substance, particles of a substance, and, pharmaceutical composition
AU2002225193A AU2002225193C1 (en) 2001-01-26 2002-01-21 Process for preparing particles
MXPA03006537A MXPA03006537A (en) 2001-01-26 2002-01-21 Process.
PT02715546T PT1357901E (en) 2001-01-26 2002-01-21 Process for preparing particles
US10/250,868 US7108867B2 (en) 2001-01-26 2002-01-21 Process for preparing particles
SI200230521T SI1357901T1 (en) 2001-01-26 2002-01-21 Process for preparing particles
IL15672002A IL156720A0 (en) 2001-01-26 2002-01-21 Process for preparing particles of a substance, particles obtained by the process and pharmaceutical compositions comprising such particles
CN02804101.1A CN1298312C (en) 2001-01-26 2002-01-21 Preparation method of particle of substance, particle of substance and pharmaceutical composition thereof
HK04105963.8A HK1063157B (en) 2001-01-26 2002-01-22 Process for preparing particles of a substance, particles of a substance and pharmaceutical composition
DE60218285T DE60218285T2 (en) 2001-01-26 2002-01-22 PROCESS FOR PARTICLE PRODUCTION
KR1020037009726A KR100853596B1 (en) 2001-01-26 2002-01-22 Way
DK02715546T DK1357901T3 (en) 2001-01-26 2002-01-22 Process for manufacturing particles
EP02715546A EP1357901B1 (en) 2001-01-26 2002-01-22 Process for preparing particles
AT02715546T ATE354352T1 (en) 2001-01-26 2002-01-22 METHOD FOR PRODUCING PARTICLES
NZ526942A NZ526942A (en) 2001-01-26 2002-01-22 A process for preparing particles of a substance using an anti-solvent technique
JP2002559008A JP4175892B2 (en) 2001-01-26 2002-01-22 Method for producing particles
CA002433838A CA2433838A1 (en) 2001-01-26 2002-01-22 Process for preparing particles
PCT/GB2002/000261 WO2002058674A2 (en) 2001-01-26 2002-01-22 Process for preparing particles
ES02715546T ES2281509T3 (en) 2001-01-26 2002-01-22 PROCESS TO PREPARE PARTICLES.
ZA200304953A ZA200304953B (en) 2001-01-26 2003-06-25 Process for preparing particles.
IL156720A IL156720A (en) 2001-01-26 2003-06-30 Process for preparing particles of a substance
NO20033241A NO20033241D0 (en) 2001-01-26 2003-07-17 Approach
US11/521,631 US7829123B2 (en) 2001-01-26 2006-09-15 Process
CY20071100570T CY1106550T1 (en) 2001-01-26 2007-04-26 PROCEDURE FOR THE PREPARATION OF PARTICLES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0102075.9A GB0102075D0 (en) 2001-01-26 2001-01-26 Process

Publications (1)

Publication Number Publication Date
GB0102075D0 true GB0102075D0 (en) 2001-03-14

Family

ID=9907591

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0102075.9A Ceased GB0102075D0 (en) 2001-01-26 2001-01-26 Process

Country Status (21)

Country Link
US (2) US7108867B2 (en)
EP (1) EP1357901B1 (en)
JP (1) JP4175892B2 (en)
KR (1) KR100853596B1 (en)
CN (1) CN1298312C (en)
AT (1) ATE354352T1 (en)
BR (1) BR0206439A (en)
CA (1) CA2433838A1 (en)
CY (1) CY1106550T1 (en)
DE (1) DE60218285T2 (en)
DK (1) DK1357901T3 (en)
ES (1) ES2281509T3 (en)
GB (1) GB0102075D0 (en)
IL (2) IL156720A0 (en)
MX (1) MXPA03006537A (en)
NO (1) NO20033241D0 (en)
NZ (1) NZ526942A (en)
PT (1) PT1357901E (en)
SI (1) SI1357901T1 (en)
WO (1) WO2002058674A2 (en)
ZA (1) ZA200304953B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US20040202681A1 (en) * 2002-12-19 2004-10-14 Baxter International, Inc. Process for preparing pharmaceutical formulations using supercritical fluids
NZ543772A (en) * 2003-04-29 2009-05-31 Organon Nv Antisolvent crystallisation process using membranes for the purification of inorganic or organic compositions
KR20060015587A (en) 2003-05-08 2006-02-17 넥타 쎄라퓨틱스 유케이 리미티드 Particulate
JP2007507527A (en) * 2003-09-30 2007-03-29 スフェリックス， インコーポレイテッド Biologically active nanoparticle therapeutic factors
US7220456B2 (en) 2004-03-31 2007-05-22 Eastman Kodak Company Process for the selective deposition of particulate material
US7223445B2 (en) 2004-03-31 2007-05-29 Eastman Kodak Company Process for the deposition of uniform layer of particulate material
AU2006272438B2 (en) 2005-07-15 2011-08-04 Map Pharmaceuticals, Inc. Method of particle formation
NL1031224C2 (en) * 2006-02-23 2007-09-03 Friesland Brands Bv The preparation of dried particles using a supercritical medium.
US20080187568A1 (en) * 2007-02-06 2008-08-07 Sawhney Amarpreet S Polymerization with precipitation of proteins for elution in physiological solution
CA2677838C (en) 2007-02-11 2017-08-01 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
JP5307382B2 (en) * 2007-11-14 2013-10-02 日機装株式会社 How to make fine particles
CA2706684C (en) * 2007-12-07 2016-01-12 Xspray Microparticles Ab Method and arrangement for the production of particles
MX350838B (en) 2011-02-11 2017-09-18 Grain Proc Corporation * Salt composition.
EP2827885B1 (en) * 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
SMT201800492T1 (en) 2013-05-02 2018-11-09 Novo Nordisk As Oral dosing of glp-1 compounds
JP6668652B2 (en) 2015-09-18 2020-03-18 日本精工株式会社 Linear motion guide device, end cap for linear motion guide device
EP4299118A3 (en) 2018-02-02 2024-04-10 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
WO2023278145A1 (en) * 2021-06-28 2023-01-05 Micro Motion, Inc. Coriolis flow meter non-ideal fluid measurement and related methods

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0739339B2 (en) 1989-05-01 1995-05-01 アルカーメス コントロールド セラピューティクス，インコーポレイテッド Method for producing small particles of bioactive molecule
US5639441A (en) * 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
CA2234957C (en) 1995-10-17 2006-12-19 Inge B. Henriksen Insoluble drug delivery
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
GB9804379D0 (en) 1998-03-02 1998-04-22 Bradford Particle Design Ltd Method of particle formation
WO1999052504A1 (en) * 1998-04-09 1999-10-21 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
SE9801287D0 (en) 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances into carrier matrixes
GB9810559D0 (en) 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
SE9804001D0 (en) 1998-11-23 1998-11-23 Astra Ab New process
GB9828204D0 (en) 1998-12-21 1999-02-17 Smithkline Beecham Plc Process
GB9915975D0 (en) 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
GB9920558D0 (en) 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
EP1425355A1 (en) * 2001-07-12 2004-06-09 Eastman Kodak Company A compressed fluid formulation
US6998051B2 (en) * 2002-07-03 2006-02-14 Ferro Corporation Particles from supercritical fluid extraction of emulsion
JP2007516259A (en) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー Method for preparing mixed phase co-crystal with activator
US7754243B2 (en) * 2004-08-03 2010-07-13 Clemson University Research Foundation Aqueous suspension of nanoscale drug particles from supercritical fluid processing

Also Published As

Publication number Publication date
CN1298312C (en) 2007-02-07
DE60218285D1 (en) 2007-04-05
IL156720A0 (en) 2004-01-04
JP4175892B2 (en) 2008-11-05
JP2004521891A (en) 2004-07-22
AU2002225193B2 (en) 2006-07-27
CN1487825A (en) 2004-04-07
CA2433838A1 (en) 2002-08-01
US7108867B2 (en) 2006-09-19
ATE354352T1 (en) 2007-03-15
DE60218285T2 (en) 2007-11-15
IL156720A (en) 2010-03-28
DK1357901T3 (en) 2007-06-04
BR0206439A (en) 2003-12-30
ES2281509T3 (en) 2007-10-01
US20070009604A1 (en) 2007-01-11
HK1063157A1 (en) 2004-12-17
WO2002058674A2 (en) 2002-08-01
US7829123B2 (en) 2010-11-09
MXPA03006537A (en) 2003-09-22
US20040058007A1 (en) 2004-03-25
SI1357901T1 (en) 2007-08-31
NO20033241L (en) 2003-07-17
NO20033241D0 (en) 2003-07-17
KR100853596B1 (en) 2008-08-22
KR20030070921A (en) 2003-09-02
NZ526942A (en) 2005-04-29
EP1357901B1 (en) 2007-02-21
ZA200304953B (en) 2004-08-25
EP1357901A2 (en) 2003-11-05
WO2002058674A3 (en) 2002-11-21
CY1106550T1 (en) 2012-01-25
PT1357901E (en) 2007-05-31

Similar Documents

Publication Publication Date Title
GB0102075D0 (en) Process
ATE377044T1 (en) GEL BASED ON POLYSACCHARIDES
ATE459415T1 (en) MICROWAVE-ASSISTED PEPTIDE SYNTHESIS
MY143253A (en) Method and device for stripping ammonia from liquids
WO2001058940A3 (en) Adenoviral capsid containing chimeric protein IX
DK1077760T3 (en) Method and apparatus for forming particulate products
ATE444112T1 (en) DISPERSIONS OF SILICONES
NZ532395A (en) Supercritical fluids processing: preparation of protein microparticles and their stabilisation
ATE349460T1 (en) REFOLDING OF PROTEIN AGGREGATES AND INCLUSION PARTICLES BY HIGH PRESSURE
EP0335654A3 (en) Odorant-binding protein from rat
Snellman et al. Haptoglobin acting as a natural inhibitor of cathepsin B activity
TNSN99231A1 (en) PROCESS FOR THE PRODUCTION OF A METHANE-RICH LIQUID OF A METHANE-RICH GAS
Iwata et al. Rabbit pulmonary angiotensin-converting enzyme: the NH2-terminal fragment with enzymatic activity and its formation from the native enzyme by NH4OH treatment
EP1499296A4 (en) Formulation of fine particles using liquefied or dense gases
IL160684A0 (en) Process for coating solid particles
ATE316575T1 (en) RECOMBINANT MISTLE ECTIN
BG106842A (en) Human heparanase-related polypeptide and nucleic acid
ATE498646T1 (en) METHOD FOR PRODUCING MICROPARTICLES
BR9915484A (en) Process for the continuous isolation of active proteins
Huang et al. Effects of glycine, water, ammonia, and ammonium bicarbonate on the oligomerization of methionine
ATE524484T1 (en) IN VITRO PROCESS FOR SEQUENCE-SPECIFIC BIOTINYLATION OF POLYPEPTIDES
Deyrup et al. A new substrate for porcine pepsin possessing cryptic fluorescence properties
JPS53130054A (en) Orientation treatment method of liquid crystal cells
Azhazha et al. Application of the mass-spectrometer in composition control of the ingots upon electron-beam melting of metals
KR890701754A (en) Method for preparing purified indole aqueous solution

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)